Căpușă, C.; Chirculescu, B.; Vladu, I.; Viaşu, L.; Lipan, M.; Moţa, E.; Mircescu, G.
July 2016
Acta Endocrinologica (1841-0987);Jul-Sep2016, Vol. 12 Issue 3, p282
Academic Journal
Background. There are scarce data about prevalence of mineral metabolism (MM) disorders in Romanian predialysis patients, so we assessed their occurrence and relationships in mild to severe chronic kidney disease (CKD). Methods. One hundred fifteen non-dialysis CKD (eGFR 31, 95% CI 29-35mL/min) and 33 matched non-CKD subjects entered this multicentric, cross-sectional study. Serum 25-hydroxyvitamin D (25OHD), intact parathyroid hormone (iPTH), phosphate (PO4), total calcium (tCa) and alkaline phosphatase (AP) were measured, along with demographic and past medical history data. Results. Hypovitaminosis D was equally prevalent in Controls and CKD (91% vs. 96% had 25OHD<30ng/mL). Increasing proportions of hyperparathyroidism (33% - stage 2 to 100% - stage 5; p<0.001) and hyperphosphatemia (2% - stage 3 to 38% - stage 5; p<0.001) were found. Hypocalcemia was more prevalent in stage 5 (25% vs. 6% in stage 4, none in stage 3 and Controls, p<0.001). Mineral metabolism parameters correlated with eGFR. In addition, iPTH was directly associated with PO4, AP, and urinary albumin-tocreatinine ratio (ACR), but inversely with tCa and 25OHD, while negative correlation of 25OHD with age, AP, ACR, and C-reactive protein emerged. In multiple regression, eGFR was the only predictor of iPTH (Beta -0.68, 95%CI -1.35 to -0.90, R2 0.46, p<0.001), whereas age and ACR were the determinants of 25OHD (a model which explained 14% of its variation). Conclusions. Hypovitaminosis D was very common irrespective of CKD presence and severity, and it seems worsened by older age and higher albuminuria. Hyperparathyroidism preceded hyperphosphatemia and hypocalcemia, and it seems mostly dependent on kidney function decline.


Related Articles

  • Age-dependent parathormone levels and different CKD-MBD treatment practices of dialysis patients in Hungary - results from a nationwide clinical audit. Kiss, István; Kiss, Zoltán; Ambrus, Csaba; Szabó, András; Szegedi, János; Balla, József; Ladányi, Erzsébet; Csiky, Botond; Árkossy, Ottó; Török, Marietta; Túri, Sándor; Kulcsár, Imre // BMC Nephrology;2013, Vol. 14 Issue 1, p1 

    Background: Achieving target levels of laboratory parameters of bone and mineral metabolism in chronic kidney disease (CKD) patients is important but also difficult in those living with end-stage kidney disease. This study aimed to determine if there are age-related differences in chronic kidney...

  • Correlation of new bone metabolic markers with conventional biomarkers in hemodialysis patients. Takano, Mari; Okano, Kazuhiro; Tsuruta, Yuki; Yamashita, Tetsuri; Echida, Yoshihisa; Miwa, Naoko; Kimata, Naoki; Akiba, Takashi; Nitta, Kosaku // Clinical & Investigative Medicine;Oct2011, Vol. 34 Issue 5, pE267 

    Background: New bone metabolic markers have become available clinically for evaluating chronic kidney disease mineral and bone disorders (CKD-MBD).The aim of this study was to correlate these new bone metabolic markers with conventional markers in regular hemodialysis (HD) patients. Methods: One...

  • High alkaline phosphatase levels in hemodialysis patients are associated with higher risk of hospitalization and death. Blayney, Margaret J.; Pisoni, Ronald L.; Bragg-Gresham, Jennifer L.; Bommer, Juergen; Piera, Luis; Saito, Akira; Akiba, Takashi; Keen, Marcia L.; Young, Eric W.; Port, Friedrich K. // Kidney International;Sep2008, Vol. 74 Issue 5, p655 

    We evaluated risks associated with elevated alkaline phosphatase in hemodialysis patients using longitudinal data from the Dialysis Outcomes and Practice Patterns Study, a prospective observational study of hemodialysis patients in 12 countries. Alkaline phosphatase levels were normalized by the...

  • Acetate free citrate-containing dialysate increase intact-PTH and BAP levels in the patients with low intact-PTH. Kuragano, Takahiro; Furuta, Minoru; Yahiro, Mana; Kida, Aritoshi; Otaki, Yoshinaga; Hasuike, Yukiko; Matsumoto, Akihide; Nakanishi, Takeshi // BMC Nephrology;2013, Vol. 14 Issue 1, p1 

    Background: Recently, acetate-free citrate containing dialysate (A(-)D) was developed. We have already reported about the significant effect of A(-)D on metabolic acidosis, anemia, and malnutrition in maintenance hemodialysis (MHD) patients. In this study, we compared the effect of A(-)D and...

  • Serum levels of TRAP5b, a new bone resorption marker unaffected by renal dysfunction, as a useful marker of cortical bone loss in hemodialysis patients. Shidara, Kaori; Inaba, Masaaki; Okuno, Senji; Yamada, Shinsuke; Kumeda, Yasuro; Imanishi, Yasuo; Yamakawa, Tomoyuki; Ishimura, Eiji; Nishizawa, Yoshiki // Calcified Tissue International;Apr2008, Vol. 82 Issue 4, p278 

    Tartrate-resistant acid phosphatase (TRAP) 5b is a new marker of bone resorption that is unaffected by renal dysfunction. The significance of TRAP5b was assessed in hemodialysis (HD) patients. Serum concentrations of TRAP5b and cross-linked N-telopeptide of type I collagen (NTX) were determined...

  • Serum Alkaline Phosphatase Levels are Not Associated with Increased Death Risk in Prevalent Hemodialysis Patients: 5-Year Experience in a Single Hemodialysis Center. Zhu, Jin-Gang; Cheng, Ben-Chung; Lee, Wen-Chin; Li, Lung-Chih; Lee, Chih-Hsiung; Long, Gang; Chen, Jin-Bor // Kidney & Blood Pressure Research;Jul2016, Vol. 41 Issue 4, p498 

    Background/Aims: Although high serum alkaline phosphatase (ALP) levels were reported as predictive factors for death risk in dialysis patients on the basis of large databank analyses, the real scenario in a single hemodialysis (HD) center is unknown. Methods: In this study, a 5-year cohort of...

  • Correlation between Serum Parathyroid Hormone and Markers of Bone Metabolism in Hemodialysis Patients. Atapour, Abdolamir; Sadeghi, Hamid Mir-Mohammad; Mahboobnia, Khadijeh; Pourfarzam, Morteza // Journal of Isfahan Medical School;Sep2013, Vol. 31 Issue 244, p1059 

    Background: Renal osteodystrophy is a common finding in patients with chronic kidney disease (CKD) requiring dialysis (stages 3-5). Increased serum activity of bone isoform alkaline phosphatase is a good marker for investigating uremic osteodystrophy in these patients. Considering the important...

  • Is parathyroid hormone measurement useful for the diagnosis of renal bone disease? Drüeke, T. B. // Kidney International;Mar2008, Vol. 73 Issue 6, p674 

    The non-invasive diagnosis of bone turnover in patients with chronic kidney disease (CKD) remains difficult compared with bone histomorphometry as the gold standard. Most clinicians rely on surrogate markers, mainly serum parathyroid hormone and total alkaline phosphatases, in association with...

  • 1,25(OH)2D3 administration in moderate renal failure: A prospective double-blind trial. Baker, Laurence R. I.; Abrams, S. M. Louise; Roe, Christopher J.; Faugere, Marie-Claude; Fanti, Paolo; Subayti, Yahya; Malluche, Hartmut H. // Kidney International;Feb1989, Vol. 35 Issue 2, p661 

    This study represents the first randomized prospective, double-blind, placebo-controlled trial of the efficacy of 1,25(OH)2D3 on bone histology and serum biochemistry in patients with mild to moderate renal failure. Sixteen patients with chronic renal impairment (creatinine clearance 20 to 59 ml...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics